Synthetic Biologics, Inc., a clinical-stage company, focuses on developing therapeutic microbiome preservatives to protect and restore patient health in the United States. The main product candidates include SYN-004, Phase III clinical trials to protect intestinal microbiomas from the effects of intravenous beta-lactam antibiotics commonly used in the digestive tract to prevent microbioma damage and Clostridium deficiency infection (CDI). ), Pathogen overgrowth, the occurrence of antibiotic resistance (AMR), and acute graft-versus-host disease in allogeneic hematopoietic cell transplants.

The company is also developing SYN-010, which is in phase IIb / III clinical trials to reduce the effect of methane-producing methane on intestinal microbiomas and to treat causes of irritable bowel syndrome with constipation. and SYN-020, an oral composition for the intestinal alkaline phosphatase enzyme for the treatment of both local GI and systemic diseases and therapy with monoclonal antibodies that prevent and treat whooping cough. Also, clinical-stage products include SYN-006 and SYN-007 for the prevention of CDI, pathogen overgrowth and AMR; and SYN-005 for the prevention and treatment of pertussis.

Syn stock

┬áSynthetic Biologics, Inc. syn stock working with Intrexon Corporation, the University of Texas at Austin, and Cedars-Sinai Medical Center. This company was formerly known as Adeona Pharmaceuticals, Inc. and changed its name to Synthetic Biologics, Inc. In February 2012, Synthetic Biologics, Inc. was founded in 2001 and is headquartered in Rockville, Maryland. Synthetic Biologics is expected to release its next quarterly earnings announcement on Thursday, August 13, 2020. Media reports on SYN shares are somewhat biased this week, reports the InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand news sources and blogs. The company negatively assessed the range of companies listed on a scale of five to five, with the lowest yield being five. Synthetic Biologics obtained a mood rating of 2.0 on the InfoTrie scale. They also submit news reports for companies at 10.0 out of 10, which means that the most recent reporting will most likely affect the company’s stock price shortly.

Major shareholders

The reverse split of Synthetic Biological stocks on the morning of August 13, 2018. The reverse split of shares 1-35 was announced on Wednesday, August 1, 2018. The number of shares held by shareholders is adjusted after the closing bell on Friday, August 10, 2018. An investor who has 100 Synthetic Biology shares before the reverse split has 3 shares after the split. Stock analysts issued a twelve-month price target for Synthetic Biologics shares. Their estimates range from $ 1.25 to $ 1.25. On average, they expect Synthetic Biologics to reach $ 1.25 next year. This shows the possibility of a 286.3% increase in the current stock price. Synthetic Biology syn stock shares are owned by various institutional and private investors. Major institutional shareholders include UBS Group AG (0.63%) and Sabby Management LLC (0.42%). Domestic companies that have interests in Synthetic Biology include Randal J Kirk and Steven A Shallcross. If you want to know more stock information like isr stock, you can visit at